Research Pulse — 2026-09-07 | Brown Biotech

# Research Pulse — 2026-09-07
_Generated 2026-09-07 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 7일 (월요일) · Accelerating(가속 Day)**

9/7(가속)→9/6(Accelerating)→9/5(Accelerating)→9/4(Accelerating)→9/3(Accelerating)→9/2(Accelerating)→9/1(Accelerating)→8/31(Accelerating)→...→7/14(가속). 9월 들어 AI × Bioresearch 분야가 **다체계 통합(Convergence)과 기술 검증(Validation) 단계에서 가속(Accelerating) 단계로 전환하는 날** — CRISPR-Cas9 치료제 임상 Trials 현황과 체외監VISUAL monitoring toolkit 체계 확립(Chakraborty Molecular Therapy 2026 + Freedman Nature Reviews Genetics 2026), AI drug discovery의 全단계 통합과 AI-originated Phase IIa 성공/Phase I 정지 사례로 실전 검증加速确认(Ali Drug Development Research 2026 + Seyhan Critical Reviews Oncology 2026), AlphaFold3의 실험 데이터 통합으로 NMR·X-ray·cryo-EM 측정-일관 구조 ensembles 생성 확인(Maddipatla Nature Biotechnology 2026), CAPTAIN이 4M cells + 382 surface proteins로 transcriptomes+proteomes 통합 multimodal foundation model 실현 확인(Ji Nature Communications 2026), 2025년 FDA protein kinase inhibitor 10개新規승인과 2026 Q2-Q1 예상 승인 60개 pipeline 확 regroup(Joseph AJHP 2026 + Roskoski Pharmacological Research 2026), SCLC 75명 600K+ cells spatial transcriptomics으로 3개 LNM-enriched malignant subclusters 발견(Zhang Cell Reports Medicine 2026)이 동시에 진행된다.

Accelerating은 8월 마지막 주 Expanding/Diversifying의 다음 단계다. 오늘 6개 전선은 검증된 기술들이 **가속화(Accelerating) 단계로切替하여 실전 적용의 속도를 높이는 날**이다.

*출처: [Chakraborty CRISPR Therapeutics Clinical Trials Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Freedman Somatic Cell Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Maddipatla AlphaFold3 Experiment-Guided Nature Biotechnology 2026](https://consensus.app/papers/details/8fe5df980a9957f4b5cca5e68f6f2a40/), [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Roskoski FDA Protein Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals Q2 2026 Q1 2027 AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/), [Zhang SCLC Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)*

*#AcceleratingDay #CRISPR #Chakraborty #MolecularTherapy #Freedman #NatureReviewsGenetics #Ali #AIDrugDiscovery #Seyhan #Maddipatla #AlphaFold3 #NatureBiotechnology #Ji #CAPTAIN #NatureCommunications #Roskoski #KinaseInhibitor #Joseph #AJHP #Zhang #SCLC #CellReportsMedicine #Accelerating #Convergence #Validation #ClinicalTranslation #AI #Biotech #DailyReport*

---

### Post 2: CRISPR & Gene Editing — 체외監VISUAL Monitoring Toolkit 체계와 Hematological Disorders 적용加速

🧪 **[CRISPR/Gene Editing] CRISPR-Cas9 치료제 임상 Trials 현황과 체외監VISUAL monitoring toolkit 체계 확립(Chakraborty Molecular Therapy 2026 + Freedman Nature Reviews Genetics 2026) + CRISPR-Cas9가 hematological disorders 치료에서 translational/clinical applications加速確認(Singh Cureus 2026): CRISPR 기술의 가속화(Accelerating) 단계 도래 확인**

CRISPR 유전자 편집 기술의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[1][2][3].

**CRISPR-Cas9 치료제 임상 Trials 현황: 치료제 개발 Epoch 확립[1]**
Chayanon Chakraborty et al.(Molecular Therapy 2026)의 review는 CRISPR-Cas9 치료제 개발의 현재 상태를 포괄적으로 분석한다. **Casgevy 역사적 승인**: UK MHRA가 2023년 11월 16일首款 CRISPR-Cas9 치료제로 Transfusion-dependent β-thalassemia(TDT) 승인, 이후 Sickle Cell Disease(SCD) 추가 승인. **FDA 승인**: 2023년 12월 8일 Casgevy SCD 치료제 승인. **치료 영역 확대**: hemoglobinopathies, cancer immunotherapies, HIV treatment, complex diseases로 적용 범위 확장. **Biopharmaceutical industry-academia collaboration 모델**: 치료제 개발의 협력 체계. **Patent landscape**: CRISPR-Cas9 기술의 지적재산권 체계. **Challenges**: off-target effects, delivery systems, long-term safety, cost-effectiveness. 핵심: CRISPR-Cas9 치료제의 Epoch 확립 — 임상 적용의 가속화(Accelerating) 단계 도래.

**체외監VISUAL Monitoring Toolkit: Somatic Cell Genome Editing 안전성/유효성 평가 체계[2]**
Benjamin S. Freedman et al.(Nature Reviews Genetics 2026)의 review는 CRISPR-based genome editing therapeutics의 biological effects를 모니터링하는 emerging technologies를 분석한다. **Preclinical-to-clinical toolkits**: safety와 efficacy 평가 toolkit. **측정 스케일**: (1) DNA 수준 — editing outcomes 직접 측정, (2) Human microphysiological systems — organoids, organs-on-chips, (3) Non-invasive in vivo imaging — biodistribution 추적. **On-target과 off-target editing outcomes 측정**: functional responses 이해를 위한 필수 benchmark. **Microphysiological systems의 가치**: 편집 전략의표현형 평가 — varied organ lineages와 disease states. **Non-invasive imaging의 역할**: genome editors와 edited cells의 in vivo 추적. 핵심: Somatic cell genome editing monitoring toolkit 체계 확립 — CRISPR 치료제의 가속화(Accelerating) 안전성 기반.

**CRISPR-Cas9 Hematological Disorders 적용: Translational/Clinical Applications加速[3]**
Abhay Kumar Singh et al.(Cureus 2026)의 review는 CRISPR-Cas9의 hematological disorders 적용을 분석한다. **적용 영역**: hematopoietic stem cell editing, hemoglobinopathies 교정, immune cell engineering, CAR-based therapies. ** Delivery platforms**: AAV, lipid nanoparticles(LNPs), electroporation. **High-fidelity nuclease designs**: 편집 정확도 향상. **Challenges**: off-target effects, genomic stability, manufacturing scalability, regulatory oversight, ethical governance. **임상 Trials outcomes**: sustained therapeutic benefit와 expanding feasibility 확인. **Long-term clinical monitoring**: durability와 safety 평가 필수. 핵심: CRISPR-Cas9가 hematological disorders에서 translational/clinical applications加速 — 치료 적용의 가속화(Accelerating) 확인.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 ISS spatial profiling, mRNA/LNP de-targeting, RNA-LNP PE7, DrugCLIP contrastive learning, Big Data Healthcare 4Vs framework, GPR18 neuroinflammation, CAF-T cell adenosine axis, CAPItello-281 biomarker-guided approval 등의 **跨영역 확산(Expanding)**을 제시했다면, 오늘은 **Chakraborty Molecular Therapy**으로 **Casgevy 역사적 승인 Epoch 확립과 치료 영역 확대**를(치료제 개발 Epoch), **Freedman Nature Reviews Genetics**으로 **체외監VISUAL monitoring toolkit 체계 확립**을(안전성 기반), **Singh Cureus**으로 **hematological disorders에서 translational applications加速**를(임상 적용 가속화) 동시에 제시한다. Expanding(9/4-9/6) → 치료제 Epoch + 안전성 체계 + 임상 적용 가속화 Accelerating(9/7).

실무 함의: 유전자 치료 전달 기술팀에서 Freedman et al.의 monitoring toolkit 접근법을 분석하여 CRISPR 치료제 안전성 평가 전략을 수립해야 한다.

*출처: [Chakraborty CRISPR Therapeutics Clinical Trials Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Freedman Somatic Cell Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Singh CRISPR Hematological Disorders Cureus 2026](https://consensus.app/papers/details/841e224ecfd9517e8fbbdfeaa4e0a78c/)*

*#CRISPR #GeneEditing #Chakraborty #MolecularTherapy #Casgevy #TDT #SCD #Freedman #NatureReviewsGenetics #Monitoring #Organoids #OrgansOnChips #InVivoImaging #Singh #Cureus #Hematological #HematopoieticStemCell #CAR #AcceleratingDay #GenomeEditing #ClinicalTranslation #Safety #Epoch #Therapeutic*

---

### Post 3: AI 신약 — AI-Originated Phase IIa 성공과 Phase I 정지 사례로 실전 검증加速

💊 **[AI 신약] AI-driven drug discovery의 全단계 통합과 AI-originated Phase IIa 성공/Phase I 정지 사례로 실전 검증加速確認(Ali Drug Development Research 2026 + Seyhan Critical Reviews Oncology 202cent 2026 + Mao Frontiers Pharmacology 2026): AI drug discovery의 가속화(Accelerating) 단계 도래 확인**

AI-Driven Drug Discovery의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[4][5][6].

**AI Drug Discovery & Development: 全단계 통합과 실전 검증[4]**
M. Ali et al.(Drug Development Research 2026)의 review는 AI의 drug discovery and development에서의 역할을 포괄적으로 분석한다. **전환기**: AI가 drug discovery paradigm을 재구성 — machine learning, deep learning, NLP로 target identification, hit finding, lead optimization, drug repurposing 지원. **AI-driven in silico platforms의 가치**: toxicity, pharmacokinetics, developability 예측으로 late-stage attrition 감소. **Collaborative models의 중요성**: AI developers와 pharmaceutical industries 사이 협업으로 translational outcomes加速. **Challenges**: algorithmic transparency, data quality, interoperability, regulatory acceptance. 핵심: AI drug discovery의 全단계 통합 — 실전 적용의 가속화(Accelerating) 확인.

**AI in Drug Discovery: Phase IIa 성공과 Phase I 정지 사례로 실전 검증[5]**
A. Adesanya Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 임상 전환을 분석한다. **Generative modeling의 가치**: chemical space와 biological space 탐색 가속화. **AlphaFold, MoleR, PocketCrafter**: 3D molecular design tools. **Single-cell foundation models와 LLMs**: target identification에서 clinical decision까지 적용 확대. **AI-originated candidates 임상 진행 현황**: (1) Phase IIa — encouraging efficacy 보고, (2) Phase I — safety signals로 정지. **AI의 역할**: toxicity early detection 능력 입증. **Challenges**: biological complexity, patchy data, ML/pharmaceutics dual fluency scientists 부족. 핵심: AI-originated Phase IIa 성공과 Phase I 정지 사례로 실전 검증加速 — AI drug discovery의 가속화(Accelerating) 확인.

**AI Drug Discovery: Clinical Translation의Double-Edged 현실[6]**
Zihan Mao et al.(Frontiers in Pharmacology 2026)의 review는 AI drug discovery의 algorithmic foundations에서 clinical translation까지 분석한다. **Methods evolution**: CNN, RNN, GNN, GAN, VAE, Diffusion models, Transformers. **Tasks acceleration**: molecular feature extraction, drug-target affinity prediction, crystal structure prediction with polymorph stability. **Bioavailability와 manufacturability 예측**: early insight로 success rates 향상 가능. **Clinical cases 분석**: double-edged — AI-discovered candidate Phase IIa efficacy encouraging + Phase I safety signals. **향후 요구사항**: data standardization, nimble regulatory frameworks, cross-disciplinary training. 핵심: AI drug discovery clinical translation의 double-edged 현실 — 실전 검증의 가속화(Accelerating) 확인.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 DrugCLIP contrastive learning ultrafast genome-wide screening, Big Data Healthcare 4Vs framework 확장, de Oliveira Teixeira AlphaFold structures antibiotic resistance 적용 등의 **跨영역 적용 확산(Expanding)**을 제시했다면, 오늘은 **Ali Drug Development Research**으로 **AI drug discovery 全단계 통합**을(파이프라인 통합), **Seyhan Critical Reviews**으로 **AI-originated Phase IIa 성공/Phase I 정지 실전 검증**을(실전 검증), **Mao Frontiers Pharmacology**으로 **clinical translation double-edged 현실**을(실제 한계) 동시에 제시한다. Expanding(9/4-9/6) → 全단계 통합 + 실전 검증 + 한계 인식 Accelerating(9/7).

실무 함의: AI drug discovery 협업팀에서 Seyhan et al.의 실전 검증 사례를 분석하여 AI pipeline 적용 전략을 수립해야 한다.

*출처: [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Mao AI Drug Discovery Clinical Translation Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)*

*#AI #DrugDiscovery #Ali #DrugDevelopmentResearch #Seyhan #CriticalReviews #PhaseIIa #PhaseI #Mao #FrontiersPharmacology #DoubleEdged #AcceleratingDay #GenerativeModeling #AlphaFold #MoleR #PocketCrafter #ClinicalTranslation #Toxicity #Validation #Pipeline #AIIntegration*

---

### Post 4: 단백질 AI — AlphaFold3 Experiment-Guided Structures와 Adversarial Mutation 평가加速

🔬 **[단백질 AI] AlphaFold3의 실험 데이터 통합으로 NMR·X-ray·cryo-EM 측정-일관 구조 ensembles 생성 확인(Maddipatla Nature Biotechnology 2026) + AlphaFold predictions의 물리적 비현실성 문제와 arity map 기반 품질 평가 체계 확립(Sarti Bioinformatics Advances 2026) + AlphaFold/ESMFold의 adversarial mutation invariance 문제 확인(Feldman Computational Biotechnology 2026): 단백질 AI의 가속화(Accelerating) 단계 확인**

단백질 AI의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[7][8][9].

**AlphaFold3 Experiment-Guided Structures: NMR·X-ray·cryo-EM 통합[7]**
Advaith Maddipatla et al.(Nature Biotechnology 2026)의 연구는 AlphaFold3의 실험 데이터 통합 접근법을 제시한다. **AlphaFold3의 한계**: 단일 지배적 구조로 collapsed predictions —heterogeneous structures 파악 어려움. **Experiment-guided approach**: NMR spectroscopy, X-ray crystallography, cryo-EM 실험 데이터 통합. **Dynamic 데이터 통합**: site-resolved order parameters 포함. **결과**: ensemble-averaged observables가 실험과 일치 — 전통적 NMR structures보다 적은 distance restraint violations. **비현실적 alternate conformations 발견**: electron density에서 확인. 핵심: AlphaFold3 experiment-guided로 측정-일관 구조 ensembles 생성 — 단백질 AI의 가속화(Accelerating) 확인.

**AlphaFold Predictions 품질 평가: Arity Map 기반 체계[8]**
Edoardo Sarti et al.(Bioinformatics Advances 2026)의 연구는 AlphaFold predictions의 품질 평가 체계를 제시한다. **배경**: pLDDT의 한계 — 30-40% residues가 low-confidence range. **Wasserstein PCA로 arity map 정의**: 단백질을 3개群으로 분류 — well-folded proteins, intrinsically disordered proteins(IDPs), physically implausible predictions. **Per-residue scoring function(abstraqt)**: hallucinated helices와 distorted beta strands 식별. **향상된 품질 예측**: pLDDT를 보완하는 신뢰성 평가. 핵심: AlphaFold predictions의 arity map 기반 품질 평가 체계 확립 — 단백질 AI의 가속화(Accelerating) 기반.

**AlphaFold/ESMFold Adversarial Mutation Invariance: 설계 의존성 문제 확인[9]**
J. Feldman et al.(Computational and Structural Biotechnology Journal 2026)의 연구는 AlphaFold3의 adversarial mutation 평가를 수행한다. **40% 잔기 치환에도 구조 불변**: 의도적 탈안정화 치환에서도 예측 구조 유지. **10% 잔기 결여에도 불변**: 실험적 fold-switching proteins에서도 마찬가지. **Confidence metrics 불신뢰**: 가장 정확한 구조를 35% 이하에서만 선택. **ESMFold 상대적 우위**: 더 높은 mutation sensitivity — 그러나 완벽하지 않음. **Implication**: template-based pattern matching 의존 → mutation-effect interpretation, confidence-guided model selection에 영향. 핵심: AlphaFold/ESMFold adversarial mutation invariance 문제 확인 — 단백질 AI의 한계 인식 강화.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 de Oliveira Teixeira AlphaFold structures antibiotic resistance 적용, Tortolani GPR18 AlphaFold neuroinflammation, Dhir AI computational drug design workflow 등의 **跨영역 적용 확산(Expanding)**을 제시했다면, 오늘은 **Maddipatla Nature Biotechnology**으로 **AlphaFold3 experiment-guided structures로 측정-일관 ensembles 생성**을(정확도 향상), **Sarti Bioinformatics Advances**으로 **arity map 기반 품질 평가 체계 확립**을(신뢰성 향상), **Feldman Computational Biotechnology**으로 **adversarial mutation invariance 문제 확인**을(한계 인식) 동시에 제시한다. Expanding(9/4-9/6) → 정확도 향상 + 품질 평가 체계 + 한계 인식 Accelerating(9/7).

실무 함의: 전산단백질 설계팀에서 Maddipatla et al.의 experiment-guided 접근법을 분석하여 구조 예측 정확도 향상 전략을 수립해야 한다.

*출처: [Maddipatla AlphaFold3 Experiment-Guided Nature Biotechnology 2026](https://consensus.app/papers/details/8fe5df980a9957f4b5cca5e68f6f2a40/), [Sarti AlphaFold Quality Assessment Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Feldman AlphaFold Adversarial Mutations Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)*

*#ProteinAI #AlphaFold3 #Maddipatla #NatureBiotechnology #ExperimentGuided #NMR #CryoEM #Xray #Sarti #BioinformaticsAdvances #ArityMap #QualityAssessment #Feldman #ComputationalBiotechnology #AdversarialMutation #Invariance #AcceleratingDay #ProteinStructure #Validation #Accuracy #Reliability*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN Multimodal 통합과 SCMBench 성능 격차 재확인

🬬 **[Single-Cell Multi-Omics Foundation Model] CAPTAIN이 4M cells + 382 surface proteins로 transcriptomes+proteomes 통합 multimodal foundation model 실현 확인(Ji Nature Communications 2026) + SCMBench로 FM vs DM 성능 격차 재확인 + lightweight adaptation으로 bridging(Wang Nature Communications 2026) + CEN/Xia Single-Cell Spatial Omics comprehensive review로 방법론与应用 종합(Cen MedComm 2026): single-cell foundation model의 가속화(Accelerating) 단계 도래 확인**

Single-Cell Foundation Model의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[10][11][12].

**CAPTAIN: Multimodal Foundation Model — Transcriptomes + Proteomes 통합[10]**
Boya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model을 제시한다. **기존 한계 극복**: 기존 single-cell foundation models이 transcriptomes만 훈련 — proteomic landscape 파악 부족. **CAPTAIN 혁신**: 4 million+ single cells에서 concurrently measured transcriptomes와 382 surface proteins 통합 훈련. **Human + mouse 다양한 조직**: cross-modality dependencies modeling. **일반화 성능**: fine-tuning과 zero-shot settings 모두에서 robust generalization. **Downstream tasks**: protein imputation, expansion, cell type annotation, batch harmonization. **COVID-19 severity 관련 발견**: immune interaction patterns 관련. 핵심: CAPTAIN으로 transcriptomes + proteomes 통합 multimodal foundation model 실현 — 단일세포 AI의 가속화(Accelerating) 확인.

**SCMBench: FM vs DM 성능 격차 재확인 + Lightweight Adaptation[11]**
Yixuan Wang et al.(Nature Communications 2026)의 연구는 single-cell multi-omics integration에서 FM vs DM 성능을 재평가한다. **23 methods 평가**: integration accuracy, biomarker detection, trajectory inference, batch effect correction. **FMs < DMs 확인**: foundation models이 state-of-the-art domain-specific models에 미치지 못함. **Lightweight adaptation으로 bridging**: performance gap 해소 가능. **핵심 시사점**: foundation models의 현재 한계 + 실전 적용 가능성 동시 존재. 핵심: SCMBench로 FM vs DM 격차 재확인 + lightweight adaptation bridging — single-cell AI의 가속화(Accelerating) 기반.

**Single-Cell and Spatial Omics: Comprehensive Review[12]**
Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell과 spatial omics의 방법론과 applyplications를 종합한다. **기술 발전**: high-throughput, subcellular, multiomics profiling. **Computational advances**: generative AI와 foundation models. **적용**: biomarker discovery, therapeutic target identification, precision medicine. **Challenges**: methodological advances와 biomedical discovery 사이 격차. 핵심: Single-Cell Spatial Omics의 종합적 review — 방법론与应用의 가속화(Accelerating) 확인.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 Kendiukhov foundation model adversarial validation, Abir CFM-GP conditional flow matching, Fan scYeast biological-knowledge-guided 등의 **跨영역 적용 확산(Expanding)**을 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN 4M cells + 382 proteins multimodal 통합**을(multimodal 통합), **Wang Nature Communications**으로 **SCMBench FM vs DM 격차 재확인 + lightweight adaptation**을(성능 검증), **Cen MedComm**으로 **single-cell spatial omics 종합 review**를(방법론与应用 종합) 동시에 제시한다. Expanding(9/4-9/6) → multimodal 통합 + 성능 검증 + 종합 review Accelerating(9/7).

실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN 접근법을 분석하여 multimodal integration strategy를 수립해야 한다.

*출처: [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Foundation Models Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)*

*#SingleCell #FoundationModel #CAPTAIN #Ji #NatureCommunications #Multimodal #Proteomics #Transcriptomics #Wang #SCMBench #FMvsDM #LightweightAdaptation #Cen #MedComm #SpatialOmics #AcceleratingDay #BatchHarmonization #CellTypeAnnotation #ProteinImputation #COVID19*

---

### Post 6: FDA/규제 — 2025년 Protein Kinase Inhibitor 10개新規승인과 2026-2027 Pipeline 예상

📋 **[FDA/규제] 2025년 FDA protein kinase inhibitor 10개新規승인과 94개 전체 현황 확인(Roskoski Pharmacological Research 2026) + 2026 Q2-Q1 2027 예상 승인 60개 pipeline regroup(Joseph AJHP 2026) + 2024년 CGT 13개 승인 포함 4기관 비교 체계 재확인: FDA 규제의 가속화(Accelerating) 단계 도래 확인**

FDA/규제의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[13][14].

**2025년 Protein Kinase Inhibitor 10개新規승인: 94개 전체 현황[13]**
Robert Roskoski(Pharmacological Research 2026)의 review는 FDA 승인 protein kinase inhibitors의 2026년 현황을 분석한다. **2025년 10개新規승인**: (1) avutometinib(MEK1/2, ovarian serous carcinomas), (2) defactinib(FAK, low grade serous ovarian), (3) delgocitinib(JAK, hand eczema), (4) mirdametinib(MEK1/2, neurofibromatosis type 1), (5) remibrutinib(BTK, chronic spontaneous urticaria), (6) rilzabrutinib(BTK, chronic immune thrombocytopenia), (7) sunvozertinib(EGFR exon 21, NSCLC), (8) taletrectinib(ROS1 mutant, NSCLC), (9) vimseltinib(CSF1R, TGCT), (10) zongertinib(HER2 mutant, NSCLC). **94개 전체**: dual specificity MEK1/2 6개, protein-serine/threonine 14개, nonreceptor tyrosine 26개, receptor tyrosine 48개. **80개 경구 투여 가능**. **45개 Lipinski rule of five 위반**. 핵심: 2025년 10개 protein kinase inhibitor 신규 승인 — FDA 규제의 가속화(Accelerating) 확인.

**2026 Q2-Q1 2027 Novel Drug Approvals: 60개 Pipeline regroup[14]**
R. Joseph et al.(American Journal of Health-System Pharmacy 2026)의 review는 2026 Q2-2027 Q1 예상 승인 drug approvals를 분석한다. **60개 novel drugs**: FDA 승인 대기 상태. **치료 영역**: rare/inherited genetic disorders, immunologic/inflammatory diseases, targeted oncology, gene therapies. **Health-system pharmacists 역할**: pharmaceutical pipeline monitoring, formulary management, resource allocation, clinical programs optimization. **치료 혁신 방향**: novel therapies continues to strengthen the current drug pipeline. 핵심: 2026 Q2-Q1 2027 60개 pipeline regroup — FDA 규제의 가속화(Accelerating) 확인.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 CAPItello-281 PTEN-deficient prostate cancer biomarker-guided approval, ALS three converging approaches, BMP-7 mRNA 골 재생 등의 **Biomarker-Guided 규제 확산(Expanding)**을 제시했다면, 오늘은 **Roskoski Pharmacological Research**으로 **2025년 10개 protein kinase inhibitor 신규 승인**을(구체적 승인 현황), **Joseph AJHP**으로 **2026 Q2-Q1 2027 60개 pipeline regroup**을(예상 pipeline) 동시에 제시한다. Expanding(9/4-9/6) → 구체적 승인 현황 + 예상 pipeline regroup Accelerating(9/7).

실무 함의: 규제 기획팀에서 Roskoski et al.의 2025년 승인 현황을 분석하여 2026-2027 pipeline strategy를 수립해야 한다.

*출처: [Roskoski FDA Protein Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals Q2 2026 Q1 2027 AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/)*

*#FDA #Roskoski #PharmacologicalResearch #KinaseInhibitor #2025Approval #Joseph #AJHP #Pipeline #2026Q2 #2027Q1 #NovelDrug #AcceleratingDay #Avutometinib #Defactinib #Delgocitinib #Mirdametinib #Remibrutinib #Rilzabrutinib #Sunvozertinib #Taletrectinib #Vimseltinib #Zongertinib #Oncology #RareDisease #GeneTherapy*

---

### Post 7: Spatial Transcriptomics — SCLC 600K+ Cells Spatial Atlas와 Gastric Cancer Lymphocyte Aggregates

🗺️ **[Spatial Transcriptomics] SCLC 75명 600K+ cells spatial transcriptomics으로 3개 LNM-enriched malignant subclusters 발견(Zhang Cell Reports Medicine 2026) + Gastric cancer에서 lymphocyte-aggregated region 발견과 PD1+CD27+ CD8 T cells proximity 분석(Gao Nature Communications 2026) + Pan-cancer 12개 암종 56개 local cellular programs + 13개 recurrent niches 동시 확인(Li Cell Reports Medicine 2026): spatial transcriptomics의 가속화(Accelerating) 단계 도래 확인**

Spatial Transcriptomics의**가속화(Accelerating) 체계**가 출처에서 동시에 확인된다[15][16][17].

**SCLC Spatial Transcriptomics: 75명 600K+ Cells Atlas[15]**
Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC의 lymph node metastasis(LNM) spatial ecosystem을 분석한다. **방법**: CosMx Spatial Molecular Imager로 105개 primary/metastatic lymph node specimens 분석. **규모**: 75명 SCLC 환자, 600,000+ cells. **발견**: 3개 LNM-enriched malignant subclusters — distinct metabolic/angiogenic programs. **Immune exclusion features**: spatially correlated. **Vascular-immune crosstalk**: endothelial cells가 malignant cells 회피 + cytotoxic T cells와 functional perivascular niches 형성. **Pan-immune hotspot(PIHs-1)**: 독립적 survival predictor. 핵심: SCLC 600K+ cells spatial atlas로 3개 LNM subclusters 발견 — spatial transcriptomics의 가속화(Accelerating) 확인.

**Gastric Cancer Lymphocyte Aggregated Region: Spatial Analysis[16]**
Sen Gao et al.(Nature Communications 2026)의 연구는 gastric cancer의 spatial heterogeneity를 분석한다. **4개 spatial regions 동정**: 세포 spatial distribution variation 확인. **Lymphocyte Aggregated Region(LAR)**: lymphocyte aggregates + tertiary lymphoid structures. **Naive T cell abundance와 T cell activation pathways**: association 확인. **PD1+CD27+ CD8 T cells proximity**: CD70+LAMP3+ dendritic cells와 근접한 위치. **Group A vs Group B 차이**: 더 활성화된 lymphocytes가 Group A cancerous regions에 근접. 핵심: Gastric cancer에서 lymphocyte-aggregated region 발견 — spatial immunology의 가속화(Accelerating) 확인.

**Pan-Cancer Spatial Transcriptomics: 12개 암종 56 LCPs + 13 Niches[17]**
Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 pan-cancer spatial transcriptomic analysis를 수행한다. **373개 샘플, 12개 cancer types**: 56개 local cellular programs(LCPs) + 13개 recurrent niches 동시 확인. **Ligand-receptor 분석**: niche-shared와 niche-specific interactions. **위치 의존성**: tumor cells와 macrophages의 gene expression이 위치에 따라 다름. **예후关联**: Niche_4(macrophages + tumor cells) — poor prognosis + immunotherapy resistance; Niche_11(macrophages + immune cells) — better survival + treatment response. 핵심: Pan-cancer 56 LCPs + 13 niches로 spatial microenvironment 체계 확립 — spatial transcriptomics의 가속화(Accelerating) 확인.

**9월 4-6일 Accelerating Days vs 오늘의 차별점**: 9/4-9/6이 Koppensteiner CAF-T cell adenosine axis NSCLC, Lang CD3+ B cells DLBCL, Walberg bacterial LPS-CRC 등의 **空間生物学 Mechanism 확산(Expanding)**을 제시했다면, 오늘은 **Zhang Cell Reports Medicine**으로 **SCLC 600K+ cells atlas로 3개 LNM subclusters**를(대규모 atlas), **Gao Nature Communications**으로 **gastric cancer lymphocyte-aggregated region**을(lymphocyte spatial organization), **Li Cell Reports Medicine**으로 **pan-cancer 56 LCPs + 13 niches**를(체계적 niche 체계) 동시에 제시한다. Expanding(9/4-9/6) → 대규모 atlas + lymphocyte organization + niche 체계 Accelerating(9/7).

실무 함의: spatial transcriptomics 연구팀에서 Zhang et al.의 SCLC atlas 결과를 분석하여 tumor microenvironment targeting strategy를 수립해야 한다.

*출처: [Zhang SCLC Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer Lymphocyte Aggregated Region Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #Zhang #CellReportsMedicine #SCLC #600KCells #LNM #Gao #NatureCommunications #GastricCancer #LAR #LymphocyteAggregates #TLS #PD1 #CD27 #CD8T #Li #PanCancer #LCPs #Niches #AcceleratingDay #SpatialAtlas #TumorMicroenvironment #Niche4 #Niche11 #Macrophages #ImmuneResponse*

---

### Post 8: 오늘의 요약 — Accelerating(가속 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

9/7(Accelerating)의 핵심: 9월 들어 6개 전선이 **검증된 기술들이 가속화(Accelerating) 단계로切替하여 실전 적용의 속도를 높이는 날**이었다.

**1. CRISPR-Cas9 치료제 Epoch 확립 + 체외監VISUAL Monitoring Toolkit(Chakraborty Molecular Therapy 2026 + Freedman Nature Reviews Genetics 2026)**: Casgevy 역사적 승인 이후 치료 영역 확대 + somatic cell genome editing monitoring toolkit 체계 확립 — CRISPR 치료제의 가속화(Accelerating) 안전성 기반. [Chakraborty Molecular Therapy 2026; Freedman Nature Reviews Genetics 2026]

**2. AI-originated Phase IIa 성공/Phase I 정지 실전 검증(Ali Drug Development Research 2026 + Seyhan Critical Reviews Oncology 2026)**: AI drug discovery 全단계 통합 + Phase IIa efficacy/Phase I safety signals 동시 확인 — AI drug discovery의 실전 검증 가속화(Accelerating). [Ali Drug Development Research 2026; Seyhan Critical Reviews Oncology 2026]

**3. AlphaFold3 Experiment-Guided Structures + Arity Map 품질 평가 체계(Maddipatla Nature Biotechnology 2026 + Sarti Bioinformatics Advances 2026)**: NMR/X-ray/cryo-EM 데이터 통합으로 측정-일관 ensembles 생성 + arity map 기반 품질 평가 — 단백질 AI의 가속화(Accelerating) 정확도 향상. [Maddipatla Nature Biotechnology 2026; Sarti Bioinformatics Advances 2026]

**4. CAPTAIN Multimodal Foundation Model(Ji Nature Communications 2026)**: 4M cells + 382 proteins로 transcriptomes + proteomes 통합 multimodal foundation model — single-cell AI의 가속화(Accelerating) multimodal 통합. [Ji Nature Communications 2026]

**5. 2025년 Protein Kinase Inhibitor 10개新規승인(Roskoski Pharmacological Research 2026)**: avutometinib, defactinib, delgocitinib, mirdametinib, remibrutinib, rilzabrutinib, sunvozertinib, taletrectinib, vimseltinib, zongertinib 10개 승인 + 94개 전체 현황 — FDA 규제의 가속화(Accelerating) 확인. [Roskoski Pharmacological Research 2026]

**6. SCLC 600K+ Cells Spatial Atlas + Pan-Cancer 56 LCPs(Zhang Cell Reports Medicine 2026 + Li Cell Reports Medicine 2026)**: SCLC 75명 600K+ cells로 3개 LNM-enriched subclusters 발견 + pan-cancer 12개 암종 56 LCPs + 13 niches — spatial transcriptomics의 가속화(Accelerating) 대규모 atlas 체계. [Zhang Cell Reports Medicine 2026; Li Cell Reports Medicine 2026]

**9월 8일 전망**: Accelerating된 기술들의 실전 적용 속도와 검증 체계 강화가 핵심 변수. 특히 CRISPR monitoring toolkit의 임상 샘플 적용, AI-originated candidates의 Phase IIa 결과, CAPTAIN의 multimodal integration 확장, FDA 2026 pipeline 예상 승인이 관전.

*출처: [Chakraborty CRISPR Therapeutics Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Freedman Genome Editing Monitoring Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/), [Singh CRISPR Hematological Cureus 2026](https://consensus.app/papers/details/841e224ecfd9517e8fbbdfeaa4e0a78c/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Seyhan AI Drug Discovery Critical Reviews 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Mao AI Drug Discovery Frontiers Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Maddipatla AlphaFold3 Nature Biotechnology 2026](https://consensus.app/papers/details/8fe5df980a9957f4b5cca5e68f6f2a40/), [Sarti AlphaFold Quality Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/), [Feldman AlphaFold Mutations Computational Biotechnology 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single-Cell Spatial MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/), [Roskoski Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/), [Zhang SCLC Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#AcceleratingDay #Summary #Chakraborty #Casgevy #Freedman #Monitoring #Singh #Hematological #Ali #AIDrugDiscovery #Seyhan #PhaseIIa #Mao #ClinicalTranslation #Maddipatla #AlphaFold3 #ExperimentGuided #Sarti #ArityMap #Ji #CAPTAIN #Multimodal #Wang #SCMBench #Cen #SpatialOmics #Roskoski #KinaseInhibitor #Joseph #Pipeline #Zhang #SCLC #Gao #GastricCancer #LAR #Li #LCPs #Niches #Accelerating #Convergence #Validation #ClinicalTranslation #DailyReport*

---

## Sources

[1] [Chakraborty et al. — CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases. Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)
[2] [Freedman et al. — Monitoring Biological Effects of Somatic Cell Genome Editing. Nature Reviews Genetics 2026](https://consensus.app/papers/details/9cd05a0e1746576fb1544f7d9b38231c/)
[3] [Singh et al. — CRISPR-Cas9-Mediated Gene Editing in Hematological Disorders: Advancing Translational and Clinical Applications. Cureus 2026](https://consensus.app/papers/details/841e224ecfd9517e8fbbdfeaa4e0a78c/)
[4] [Ali et al. — Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)
[5] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)
[6] [Mao et al. — Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[7] [Maddipatla et al. — Experiment-guided AlphaFold3 resolves measurement-consistent protein ensembles. Nature Biotechnology 2026](https://consensus.app/papers/details/8fe5df980a9957f4b5cca5e68f6f2a40/)
[8] [Sarti et al. — Fold or flop: quality assessment of AlphaFold predictions on whole proteomes. Bioinformatics Advances 2026](https://consensus.app/papers/details/97d0d09907ed559998afbc1980b532f3/)
[9] [Feldman et al. — Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design. Computational and Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)
[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[11] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)
[12] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)
[13] [Roskoski — Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/)
[14] [Joseph et al. — Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027). American Journal of Health-System Pharmacy 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/)
[15] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
[16] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)
[17] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)